Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.
Read the full articleYou might also wanna read
Genetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccines
A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity. In an exploratory Phase I clin
Phages redirect vaccine immunity to attack cancer cells in mouse study
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from v
newscientist.com·18d ago
Phages redirect vaccine immunity to attack cancer cells in mouse study
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from v
newscientist.com·20d agoPhages redirect vaccine immunity to attack cancer cells in mouse study
Phages, viruses that infect bacteria, could be genetically manipulated to destroy cancerous cells using the immunity we have acquired from v
newscientist.com·20d agoNebraska Researchers Link Gut Microbe to Cancer-Fighting Immune Response
A new study from a team including University of Nebraska-Lincoln researchers is the first to show metabolites produced by certain bacteria i
Study: Gut Bacterium May Help Immune System Fight Skin Cancer
(NaturalNews) A common probiotic bacterium found in yogurt and supplements may help the immune system fight melanoma, according to a study p
Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy
Nature, Published online: 08 July 2026; doi:10.1038/s41586-026-10750-x Diet shapes obesity-associated therapeutic responses to immune checkp
Diet–microbiome synergy underlies obesity-associated immunotherapy efficacy
Nature, Published online: 08 July 2026; doi:10.1038/s41586-026-10750-x Diet shapes obesity-associated therapeutic responses to immune checkp
Comments
Sign in to join the conversation.
No comments yet. Be the first.